Bal Pharma Peer Comparison

NSE: BALPHARMA | BSE: 524824

₹84.80

₹-0.22 (-0.26%)

As on 28-Aug-2026IST

Market cap

₹135 Cr

Revenue (TTM)

₹334 Cr

P/E Ratio

18.7

P/B Ratio

1.6

Div. Yield

1.4 %

Edit

	Bal Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	135	21,501	19,125	18,253	17,766
Revenue (₹ Cr)	334	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	7.25	735.15	678.07	666.92	169.62
Net Margin (%)	2.16	26.88	28.10	20.60	6.90
RoE (%)	8.98	19.16	19.73	18.75	20.76
Price to Earnings	18.70	29.25	28.74	28.35	104.74
Price-To-Book	1.62	4.88	5.08	4.51	19.65

Income Statement (₹ Cr)

	Bal Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	334.41	2,569.77	2,287.33	3,229.67	2,432.06
Total Income	336.05	2,735.39	2,413.29	3,237.12	2,458.54
Total Expenditure	300.62	1,628.14	1,490.75	2,090.06	2,202.20
EBITDA	33.79	941.63	796.58	1,139.61	229.86
Depreciation	11.34	57.58	78.10	281.06	17.24
EBIT	22.45	884.05	718.48	858.55	212.62
Interest	17.23	7.69	0.88	190.64	5.72
Other Income	1.64	165.62	125.96	7.45	26.48
Exceptional Items	0.00	-49.16	0.00	-17.24	-5.13
Profit before Tax	6.86	992.82	843.56	658.12	228.25
Provision for Tax	-0.39	257.67	165.49	-8.80	58.63
Profit after Tax	7.25	735.15	678.07	666.92	169.62

	Bal Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	82.23	4,202.90	3,586.42	3,902.67	872.79
Minority Interest	-0.04	0.00	-12.71	-21.81	0.00
Non-Current Liabilities	44.06	91.50	28.74	1,392.75	134.50
Current Liabilities	249.23	627.48	385.94	2,077.10	981.81
Total Liabilities	335.69	4,911.11	3,207.85	6,862.28	1,879.19

	Bal Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	102.23	770.28	1,291.22	5,617.77	42.47
Current Assets	262.23	3,803.22	2,585.66	1,539.85	1,739.93
Total Assets	335.69	4,911.11	3,207.85	6,862.28	1,879.19
Total Debt*	150.38	2.50	0.55	2,421.66	0.00
Net Current Assets	13.01	3,175.74	2,199.72	-537.25	758.12
Contingent Liabilities	17.10	363.79	0.64	64.29	98.41

	Bal Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	20.32	659.75	432.37	1,065.01	65.36
Cash Flow from Investing Activities	-14.92	-71.34	-334.73	-79.97	30.80
Cash from Financing Activities	-7.84	-205.34	-38.32	-881.32	-65.59
Net Cash Inflow / Outflow	-2.44	383.07	59.32	103.72	30.57

	Bal Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	10.10	26.21	26.22	13.59	21.29
ROE (%)	8.98	19.16	19.73	18.75	20.76
ROA (%)	2.04	14.95	18.69	9.26	9.67
EBIT Margin (%)	6.71	34.40	31.41	26.58	8.74
Net Margin (%)	2.16	26.88	28.10	20.60	6.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Bal Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	13.51	10.69	15.01	9.59	31.10
EBIT Growth (%)	16.36	24.14	18.45	16.84	-12.99
Net Profit Growth (%)	0.86	-9.09	19.61	62.68	-7.49
EPS Growth (%)	0.67	14.40	17.73	67.41	-18.33
Book Value Growth (%)	7.52	17.30	23.77	10.19	7.70

	Bal Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	18.71	27.87	28.74	27.66	102.37
Price / Book Value	1.62	4.88	5.08	4.51	19.65
Dividend Yield (%)	1.42	1.60	0.16	0.55	0.51
EV/EBITDA	8.13	19.53	22.88	17.94	75.34
Market Cap (₹ Cr)	132.39	18,318.10	15,219.80	19,292.77	21,515.93

	Bal Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.39	0.00	0.00	0.24	0.00
Short term debt to equity ratio	1.39	0.00	0.00	0.14	--
Current Ratio	1.05	6.06	6.70	0.74	1.77
Quick Ratio	0.59	5.31	5.59	0.53	0.73
Interest Coverage	1.40	130.11	959.59	4.45	40.90

	Bal Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	28.00	7.07	36.10	21.07	8.79
Asset Turnover	0.94	0.52	0.63	0.45	1.39
Receivable days	115.65	29.10	110.70	54.07	35.81
Inventory Days	114.91	69.53	65.86	32.16	82.25
Payable days	202.96	76.77	105.88	140.91	124.39
Cash Conversion Cycle	27.60	21.86	70.68	-54.68	-6.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.